mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells Persist at 6 Months and Recognize the Delta Variant

Clin Infect Dis. 2022 Aug 24;75(1):e898-e901. doi: 10.1093/cid/ciab915.

Abstract

Little is known about the decay kinetics of coronavirus disease 2019 vaccine-elicited severe acute respiratory syndrome coronavirus 2-specific T cells. In this study we show a modest decline in the frequency of these T cells at 6 months and demonstrate robust expansion in response to antigen and recognition of spike peptides from the Delta variant.

Keywords: COVID; Delta variant; SARS-CoV-2; T cells; mRNA vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2*
  • T-Lymphocytes
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Vaccines, Synthetic
  • mRNA Vaccines

Supplementary concepts

  • SARS-CoV-2 variants